Residency · Residency · Family Medicine

COPD and Asthma: Diagnosis, Severity Staging, and Stepwise Therapy

Overview

Asthma and COPD are the two most common obstructive airway diseases encountered in family medicine. While they share the core feature of airflow limitation and airway inflammation, their underlying pathophysiology, natural history, and treatment strategies differ in important ways. Asthma is characterized by variable, reversible obstruction driven by eosinophilic inflammation, while COPD involves progressive, largely irreversible obstruction mediated by neutrophilic and CD8+ T-cell inflammation. Asthma-COPD overlap presents unique diagnostic and therapeutic challenges that require recognition of features from both conditions.

Asthma

Epidemiology and Pathophysiology

Asthma affects approximately 25 million Americans, with onset commonly in childhood. The disease is fundamentally an eosinophilic inflammatory process causing chronic airway inflammation, bronchial hyperresponsiveness, and variable airflow obstruction that is typically reversible either spontaneously or with treatment. Over time, chronic poorly controlled inflammation leads to airway remodeling, with structural changes that may become permanent. Common triggers include allergens, viral infections, exercise, cold air, irritants, NSAIDs, and beta-blockers.

Diagnosis

The clinical presentation of asthma includes episodic wheezing, dyspnea, chest tightness, and cough that is characteristically worse at night or in the early morning. Spirometry is the key diagnostic test, demonstrating an FEV1/FVC ratio below 0.70 (or below the lower limit of normal) with evidence of reversibility, defined as an improvement of 12% or more and at least 200 mL in FEV1 after bronchodilator administration. Peak flow variability exceeding 20% also supports the diagnosis. Importantly, normal spirometry does not exclude asthma; if clinical suspicion is high, a methacholine challenge test can identify bronchial hyperresponsiveness. Assessment for atopy through skin prick testing or allergen-specific IgE can help identify triggering allergens.

Severity Classification (Treatment-Naive)

Before initiating treatment, asthma severity is classified into four categories based on symptom frequency, nighttime awakenings, lung function, and activity limitation. Intermittent asthma involves symptoms two or fewer days per week, nighttime awakenings two or fewer times per month, normal FEV1, and no interference with daily activities. Mild persistent asthma involves symptoms more than two days per week but not daily, awakenings three to four times per month, and FEV1 at or above 80% predicted. Moderate persistent asthma features daily symptoms, nighttime awakenings more than once per week, and FEV1 between 60 and 80% predicted. Severe persistent asthma involves symptoms throughout the day, nightly awakenings, and FEV1 below 60% predicted.

Stepwise Therapy (NAEPP/GINA)

Treatment follows a stepwise approach with escalation and de-escalation based on control. At Step 1, the GINA-preferred approach is as-needed low-dose ICS-formoterol, though as-needed SABA alone remains an option. Step 2 adds daily low-dose ICS with as-needed SABA, or alternatively as-needed low-dose ICS-formoterol as both reliever and controller (GINA Track 1). Step 3 involves low-dose ICS-LABA combination therapy (such as fluticasone-salmeterol or budesonide-formoterol) or medium-dose ICS. Step 4 escalates to medium-dose ICS-LABA with consideration of adding a long-acting muscarinic antagonist (tiotropium). Step 5 uses high-dose ICS-LABA plus LAMA, with biologic therapy considered, and oral corticosteroids used only as a last resort. Step 6 involves specialist referral for biologic evaluation.

GINA Paradigm Shift: Anti-Inflammatory Reliever (AIR)

A fundamental shift in asthma management came with the GINA 2019 recommendation that SABA-only treatment is no longer recommended even for mild, intermittent asthma. The rationale is that relying solely on a bronchodilator without anti-inflammatory coverage leaves airway inflammation unchecked and increases exacerbation risk. The alternative is the SMART or MART approach, using as-needed low-dose ICS-formoterol as both reliever and controller. This strategy, supported by the SYGMA 1 and 2 trials and the Novel START trial, reduces exacerbations compared to SABA-only treatment while maintaining similar symptom control. It addresses the fundamental problem of patients using rescue inhalers without anti-inflammatory coverage.

Asthma Control Assessment

Validated tools such as the Asthma Control Test (ACT) and Asthma Control Questionnaire (ACQ) help objectively assess control. Well-controlled asthma is defined by symptoms two or fewer days per week, no nighttime awakenings, no activity limitation, SABA use two or fewer days per week, FEV1 above 80% predicted, and no exacerbations. Therapy should be stepped up if control is not achieved after two to four weeks, and stepped down after three months of sustained good control. Before escalating treatment, clinicians should always verify inhaler technique, assess medication adherence, and address comorbidities that can worsen asthma, including GERD, allergic rhinitis, obesity, and obstructive sleep apnea.

Biologic Therapies (for severe uncontrolled asthma)

For patients with severe asthma uncontrolled on maximal inhaler therapy, biologic agents target specific inflammatory pathways. Omalizumab is an anti-IgE antibody indicated for allergic asthma with elevated IgE. Mepolizumab, benralizumab, and reslizumab target the IL-5 pathway and are indicated for eosinophilic asthma with blood eosinophils at or above 300 cells per microliter. Dupilumab blocks IL-4 and IL-13 and is effective in eosinophilic or oral steroid-dependent asthma. Tezepelumab targets thymic stromal lymphopoietin (TSLP) and has broad phenotype coverage across multiple asthma endotypes.

COPD

Epidemiology and Pathophysiology

COPD is the third leading cause of death worldwide. Approximately 16 million Americans carry the diagnosis, with many more cases undiagnosed. Unlike asthma's eosinophilic inflammation, COPD involves neutrophilic and CD8+ T-cell mediated chronic inflammation that leads to progressive, largely irreversible airflow limitation. The two major pathologic components are emphysema, involving destruction of lung parenchyma, and chronic bronchitis, characterized by airway inflammation and mucus hypersecretion. Tobacco smoking is the primary risk factor, responsible for 80 to 90% of cases. Other risk factors include biomass fuel exposure (a major cause worldwide), alpha-1 antitrypsin deficiency, and occupational dust and chemical exposures.

Diagnosis

COPD should be suspected in any patient over 40 with dyspnea, chronic cough, sputum production, and a history of relevant exposures. Spirometry is required for diagnosis, demonstrating a post-bronchodilator FEV1/FVC ratio below 0.70. All patients with COPD should be tested for alpha-1 antitrypsin deficiency at least once. Chest X-ray may show hyperinflation and flattened diaphragms but is not diagnostic. CT of the chest can characterize emphysema and should be considered for lung cancer screening in eligible patients.

GOLD Severity Classification (Based on FEV1)

The GOLD classification uses post-bronchodilator FEV1 to grade airflow limitation severity: GOLD 1 (mild) with FEV1 at or above 80% predicted, GOLD 2 (moderate) at 50 to 79%, GOLD 3 (severe) at 30 to 49%, and GOLD 4 (very severe) below 30%.

ABE Assessment Tool (GOLD 2024)

The 2024 GOLD report uses the ABE assessment tool to guide initial therapy based on symptom burden and exacerbation history. Group A includes patients with low symptoms (mMRC 0 to 1 or CAT below 10) and zero to one moderate exacerbation. Group B includes patients with high symptoms (mMRC 2 or above or CAT 10 or above) and zero to one moderate exacerbation. Group E (exacerbator) includes patients with two or more moderate exacerbations or at least one hospitalization, regardless of symptom burden.

Pharmacotherapy

For Group A patients, an as-needed short-acting bronchodilator (SABA or SAMA) is sufficient. Group B patients should receive LABA or LAMA monotherapy, with LAMA generally preferred because of its superior exacerbation reduction. Group E patients require LAMA plus LABA combination therapy; if blood eosinophils are 300 or above, LABA plus ICS or triple therapy should be considered. Triple therapy combining ICS, LABA, and LAMA was shown in the IMPACT and ETHOS trials to provide a mortality benefit in exacerbation-prone patients with COPD. ICS use in COPD is indicated when eosinophils are 300 or above, when there is asthma-COPD overlap, or when exacerbations continue despite dual bronchodilator therapy. ICS carries a risk of pneumonia, particularly with fluticasone, and should be withdrawn if eosinophils are below 100 and exacerbations are not occurring.

Non-Pharmacologic Management

Smoking cessation is the single most important intervention in COPD management and is the only intervention proven to reduce the rate of FEV1 decline. Pulmonary rehabilitation improves exercise capacity, reduces dyspnea, and enhances quality of life; referral is especially valuable after an exacerbation. Long-term oxygen therapy is indicated when resting SpO2 is 88% or below or PaO2 is 55 mmHg or below, with demonstrated mortality benefit. Vaccinations should include annual influenza, pneumococcal, COVID-19, Tdap, and RSV (for those 60 and older). Palliative care should be integrated for patients with advanced COPD, addressing dyspnea management, goals of care, and advance directives.

Exacerbation Management

During an exacerbation, bronchodilator frequency should be increased. Oral corticosteroids, typically prednisone 40 mg daily for five days (the REDUCE trial demonstrated that five days is equivalent to 14), are standard. Antibiotics are indicated when there is increased sputum purulence, volume, or dyspnea, with amoxicillin-clavulanate, azithromycin, or doxycycline as first-line choices. Hospital referral is appropriate for severe dyspnea, altered mental status, failure to respond to initial treatment, hypoxemia, or hypercapnia.

Asthma-COPD Overlap (ACO)

Asthma-COPD overlap features elements of both diseases: variable airflow obstruction combined with incomplete reversibility, significant smoking history alongside atopic features or eosinophilia. No single diagnostic test confirms ACO; it is a clinical pattern recognition diagnosis. Treatment must include an ICS-containing regimen (LABA monotherapy without ICS is inappropriate), and SABA-only treatment should be avoided. Pulmonology referral is advisable for complex cases.

Inhaler Technique and Device Selection

Poor inhaler technique is the most common reason for apparent treatment failure in obstructive airway disease. Metered-dose inhalers (MDIs) require coordination between actuation and inhalation, and a spacer device significantly improves drug delivery. Dry powder inhalers (DPIs) such as Diskus, Ellipta, and Turbuhaler are inspiration-dependent and may not deliver adequate medication to patients with low inspiratory flow rates. Nebulizers are appropriate for severe cases, elderly patients, or those unable to use handheld devices. Inhaler technique should be demonstrated and reassessed at every clinical encounter.

<image>A side-by-side comparison infographic of asthma vs. COPD covering age of onset, symptoms pattern, pathology (eosinophilic vs. neutrophilic), spirometry findings (reversible vs. fixed obstruction), triggers, and treatment approach. Use parallel columns with distinct color coding and include a middle overlap zone for asthma-COPD overlap features.</image>

<image>A stepwise therapy ladder diagram for asthma management showing Steps 1 through 6, with each step listing the preferred controller and reliever medications. Include both the GINA Track 1 (ICS-formoterol as reliever) and Track 2 (SABA as reliever) approaches. Show upward arrows for stepping up and downward arrows for stepping down, with criteria for each direction.</image>

<image>An illustrated guide to inhaler devices commonly used in primary care: MDI with spacer, DPI (Diskus, Ellipta), soft mist inhaler (Respimat), and nebulizer. For each device show correct technique steps, common errors, and which patient populations are best suited for each device type.</image>

<image>The GOLD ABE assessment grid for COPD showing how symptom burden (mMRC/CAT scores) and exacerbation history combine to classify patients into Groups A, B, and E, with the recommended initial pharmacotherapy for each group including specific drug class combinations and the role of blood eosinophil levels in guiding ICS use.</image>

Clinical Pearls

Every patient diagnosed with COPD should have an alpha-1 antitrypsin level checked at least once. SABA-only treatment is no longer considered acceptable for any severity of persistent asthma, reflecting the paradigm shift toward anti-inflammatory reliever strategies. Before stepping up asthma therapy, clinicians should always assess the "treatable traits": inhaler technique, medication adherence, and comorbidities that may be worsening symptoms. Blood eosinophil count is the key guide for ICS use in COPD, with levels at or above 300 favoring ICS and levels below 100 suggesting that ICS withdrawal is safe. Prednisone courses for COPD exacerbations should be limited to five days based on the REDUCE trial, rather than the traditional 10 to 14 day courses. LAMA (tiotropium) is generally preferred over LABA for initial COPD monotherapy due to superior exacerbation reduction. Asthma patients must never receive LABA monotherapy without ICS, as this combination carries a black box warning for increased asthma-related deaths. Pulmonary rehabilitation, though dramatically underutilized, is one of the most effective interventions for reducing COPD symptom burden and improving quality of life.

References

• 2024 GOLD Report: Global Strategy for Diagnosis, Management, and Prevention of COPD
• GINA 2024: Global Strategy for Asthma Management and Prevention
• NAEPP Expert Panel Report 4: Guidelines for Diagnosis and Management of Asthma. 2020
• Rabe KF et al. ETHOS: Triple Therapy in COPD. NEJM. 2020
• Lipson DA et al. IMPACT: Triple Therapy in COPD. NEJM. 2018
• O'Byrne PM et al. SYGMA 1: PRN Budesonide-Formoterol in Mild Asthma. NEJM. 2018
• Leuppi JD et al. REDUCE Trial: Short-Course Corticosteroids for COPD Exacerbations. JAMA. 2013

Read this lecture as Markdown